Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0650

0.0%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Pogeu Mahone

To: Khris Smith who wrote (12296)	8/13/2013 7:05:25 AM
From: NTTG	1 Recommendation Read Replies (1) of 13111

Look at their end point again... IL treated tumor responses, immune responses, and survival may not be as connected as you are hoping for. Success at PII is no guarantee of success at PIII. PVCT is pushing hard to treat as many visible tumors as possible; maybe they don't trust the connection between IL, immune response and patient survival either. Problem with Allovectin is that the molecule is not cytotoxic, they only get an immune mediated effect. PVCT is not taking their time as much as they are back peddling to fill holes in their story before they can move forward with PIII. Bet they will learn a lot from allovectin PIs in the next few months that will also help them understand what to do. Happy that someone payed attention to your post now?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next